Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

Abstract The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship bet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Szymon Piatek, Grzegorz Panek, Zbigniew Lewandowski, Dominika Piatek, Przemyslaw Kosinski, Mariusz Bidzinski
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/268c85ed85a24e249946fd10674d4b6b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:268c85ed85a24e249946fd10674d4b6b
record_format	dspace
spelling	oai:doaj.org-article:268c85ed85a24e249946fd10674d4b6b2021-12-02T18:02:15ZNadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer10.1038/s41598-021-97564-12045-2322https://doaj.org/article/268c85ed85a24e249946fd10674d4b6b2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97564-1https://doaj.org/toc/2045-2322Abstract The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-125 and survival was examined by applying generalized additive models to the Cox proportional hazards model. The median CA-125 concentration after the treatment was 10 U/ml (2.7–35 U/ml). The nadir CA-125 was related to progression-free survival but not to overall survival. The risk of recurrence in patients with 11–25 U/ml and 26–35 U/ml compared to patients with ≤ 10 U/ml was 1.87 (p < 0.0024) and 2.17 (p < 0.018), respectively. An increased risk of recurrence according to the nadir CA-125 (≤ 10 U/ml vs. 11–25 U/ml and ≤ 10 U/ml vs. 26–35 U/ml) was found in patients with high-grade tumours (hazard ratio, HR = 2.08 and 2.59, respectively), advanced disease (HR = 2.38 and 2.03, respectively), serous histology (HR = 2.08 and 2.43, respectively) and after complete cytoreduction (HR = 2.7 and 2.72, respectively). No correlation between the CA-125 nadir and recurrence risk was found in patients with early-stage disease or those receiving neoadjuvant chemotherapy or bevacizumab.Szymon PiatekGrzegorz PanekZbigniew LewandowskiDominika PiatekPrzemyslaw KosinskiMariusz BidzinskiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Szymon Piatek Grzegorz Panek Zbigniew Lewandowski Dominika Piatek Przemyslaw Kosinski Mariusz Bidzinski Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
description	Abstract The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship between CA-125 and survival was examined by applying generalized additive models to the Cox proportional hazards model. The median CA-125 concentration after the treatment was 10 U/ml (2.7–35 U/ml). The nadir CA-125 was related to progression-free survival but not to overall survival. The risk of recurrence in patients with 11–25 U/ml and 26–35 U/ml compared to patients with ≤ 10 U/ml was 1.87 (p < 0.0024) and 2.17 (p < 0.018), respectively. An increased risk of recurrence according to the nadir CA-125 (≤ 10 U/ml vs. 11–25 U/ml and ≤ 10 U/ml vs. 26–35 U/ml) was found in patients with high-grade tumours (hazard ratio, HR = 2.08 and 2.59, respectively), advanced disease (HR = 2.38 and 2.03, respectively), serous histology (HR = 2.08 and 2.43, respectively) and after complete cytoreduction (HR = 2.7 and 2.72, respectively). No correlation between the CA-125 nadir and recurrence risk was found in patients with early-stage disease or those receiving neoadjuvant chemotherapy or bevacizumab.
format	article
author	Szymon Piatek Grzegorz Panek Zbigniew Lewandowski Dominika Piatek Przemyslaw Kosinski Mariusz Bidzinski
author_facet	Szymon Piatek Grzegorz Panek Zbigniew Lewandowski Dominika Piatek Przemyslaw Kosinski Mariusz Bidzinski
author_sort	Szymon Piatek
title	Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_short	Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_full	Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_fullStr	Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_full_unstemmed	Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
title_sort	nadir ca-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/268c85ed85a24e249946fd10674d4b6b
work_keys_str_mv	AT szymonpiatek nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer AT grzegorzpanek nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer AT zbigniewlewandowski nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer AT dominikapiatek nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer AT przemyslawkosinski nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer AT mariuszbidzinski nadirca125hasprognosticvalueforrecurrencebutnotforsurvivalinpatientswithovariancancer
_version_	1718378916174888960

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

Ejemplares similares